// App-Quantinova.ai

: Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study.

Researchers

Presenter

  • Aristotelis Bamias

Principal Investigators

  • Matt D. Galsky

  • Jose Angel Arranz Arija

  • Eiji Kikuchi

  • Enrique Grande

  • Xavier Garcia del Muro

  • Se Hoon Park

  • Ugo De Giorgi

  • Boris Alekseev

  • Marina Mencinger

  • Kouji Izumi

  • Javier Puente

  • Jian-Ri Li

  • Fabiola Bene-Tchaleu

  • Sanjeev Mariathasan

  • Chooi Peng Lee

  • Sandrine Bernhard

  • Maria De Santis

Medical Centers

  • Hoffmann-La Roche Ltd, Mississauga, ON, Canada

  • MD Anderson Cancer Center, Madrid, Spain

  • Taichung Veterans General Hospital, Taichung City, Taiwan

  • Research Oncology Institute, Tomsk, Russian Federation

  • Institute of Oncology Ljubljana, Ljubljana, Slovenia

  • Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY

  • St.Marianna University School of Medcine, Kawasaki, Japan

  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • Kanazawa University, Kanazawa, Japan

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • Hospital Universitario Quiron Madrid, Madrid, Spain

  • Eastern Health Clinical School, Monash University, Melbourne, Australia

  • Catalan Institute of Oncology, IDIBELL, University of Barcelona, Barcelona, Spain

  • National and Kapodistrian University of Athens, Athens, Greece

  • Charité University Hospital, Department of Urology, Berlin, Germany, and Medical University, Department of Urology, Vienna, Austria

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain

  • Genentech, Inc., South San Francisico, CA

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

Locations

  • United Kingdom

  • Republic of South Korea

  • Italy

  • Canada

  • Taiwan

  • Slovenia

  • Japan

  • Spain

  • Australia

  • Greece

  • United States

  • Russia

  • Austria

Companies

  • F. Hoffmann-La Roche

  • Feng Chi Biotech Cor

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Atezolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02807636

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved